cardiometabolic

Tissue-specific metabolomics in experimental HFpEF reveals hepatic remodelling modulated by SGLT2 inhibition

Background: Recent favourable clinical trials of sodium-glucose transporter 2 (SGLT2) inhibitors and glucagon-like-peptide-1 (GLP-1) agonists have substantially changed the management landscape for heart failure with preserved ejection fraction …